全文获取类型
收费全文 | 36208篇 |
免费 | 2295篇 |
国内免费 | 214篇 |
专业分类
耳鼻咽喉 | 450篇 |
儿科学 | 920篇 |
妇产科学 | 726篇 |
基础医学 | 4506篇 |
口腔科学 | 1349篇 |
临床医学 | 2966篇 |
内科学 | 8934篇 |
皮肤病学 | 822篇 |
神经病学 | 3053篇 |
特种医学 | 1077篇 |
外科学 | 6035篇 |
综合类 | 177篇 |
一般理论 | 9篇 |
预防医学 | 2186篇 |
眼科学 | 803篇 |
药学 | 1842篇 |
1篇 | |
中国医学 | 81篇 |
肿瘤学 | 2780篇 |
出版年
2023年 | 326篇 |
2022年 | 232篇 |
2021年 | 1318篇 |
2020年 | 723篇 |
2019年 | 1183篇 |
2018年 | 1412篇 |
2017年 | 902篇 |
2016年 | 938篇 |
2015年 | 1097篇 |
2014年 | 1499篇 |
2013年 | 1848篇 |
2012年 | 2947篇 |
2011年 | 3132篇 |
2010年 | 1682篇 |
2009年 | 1544篇 |
2008年 | 2435篇 |
2007年 | 2447篇 |
2006年 | 2250篇 |
2005年 | 2130篇 |
2004年 | 1836篇 |
2003年 | 1612篇 |
2002年 | 1415篇 |
2001年 | 342篇 |
2000年 | 282篇 |
1999年 | 327篇 |
1998年 | 253篇 |
1997年 | 196篇 |
1996年 | 159篇 |
1995年 | 198篇 |
1994年 | 167篇 |
1993年 | 175篇 |
1992年 | 175篇 |
1991年 | 134篇 |
1990年 | 112篇 |
1989年 | 112篇 |
1988年 | 101篇 |
1987年 | 84篇 |
1986年 | 92篇 |
1985年 | 72篇 |
1984年 | 80篇 |
1983年 | 73篇 |
1982年 | 75篇 |
1981年 | 76篇 |
1980年 | 52篇 |
1979年 | 53篇 |
1978年 | 44篇 |
1977年 | 49篇 |
1975年 | 37篇 |
1974年 | 36篇 |
1973年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Nicla La Verde Agostino Riva Maria Silvia Cona Arianna Gabrieli Monica Cattaneo Cinzia Fasola Giuseppe Lipari Claudia De Stradis Valentina Favorito Benedetta Lombardi Stocchetti Davide Chizzoniti Alice Covizzi Eliana Rulli Francesca Galli Lorenzo Ruggieri Anna Gambaro Sabrina Ferrario Davide Dalu Maciej S. Tarkowski 《International journal of cancer. Journal international du cancer》2023,152(4):661-671
Previous studies on the immunogenicity of SARS-CoV-2 mRNA vaccines showed a reduced seroconversion in cancer patients. The aim of our study is to evaluate the immunogenicity of two doses of mRNA vaccines in solid cancer patients with or without a previous exposure to the virus. This is a single-institution, prospective, nonrandomized study. Patients in active treatment and a control cohort of healthy people received two doses of BNT162b2 (Comirnaty, BioNTech/Pfizer, The United States) or mRNA-1273 (Spikevax, Moderna). Vaccine was administered before starting anticancer therapy or on the first day of the treatment cycle. SARS-CoV-2 antibody levels against S1, RBD (to evaluate vaccine response) and N proteins (to evaluate previous infection) were measured in plasma before the first dose and 30 days after the second one. From January to June 2021, 195 consecutive cancer patients and 20 healthy controls were enrolled. Thirty-one cancer patients had a previous exposure to SARS-CoV-2. Cancer patients previously exposed to the virus had significantly higher median levels of anti-S1 and anti-RBD IgG, compared to healthy controls (P = .0349) and to cancer patients without a previous infection (P < .001). Vaccine type (anti-S1: P < .0001; anti-RBD: P = .0045), comorbidities (anti-S1: P = .0274; anti-RBD: P = .0048) and the use of G-CSF (anti-S1: P = .0151) negatively affected the antibody response. Conversely, previous exposure to SARS-CoV-2 significantly enhanced the response to vaccination (anti-S1: P < .0001; anti-RBD: P = .0026). Vaccine immunogenicity in cancer patients with a previous exposure to SARS-CoV-2 seems comparable to that of healthy subjects. On the other hand, clinical variables of immune frailty negatively affect humoral immune response to vaccination. 相似文献
2.
Tiago Ribeiro Leal Larissa Chaves Morais de Lima rick Tssio Barbosa Neves Maria Jacinta Arêa Leo Lopes Araújo Arruda Matheus Frana Perazzo Saul Martins Paiva Júnia Maria Serra-Negra Fernanda de Morais Ferreira Ana Flvia Granville-Garcia 《International journal of paediatric dentistry / the British Paedodontic Society [and] the International Association of Dentistry for Children》2022,32(1):22-30
3.
4.
5.
6.
7.
8.
Milan Milojevic Patrick W. Serruys Joseph F. Sabik David E. Kandzari Erick Schampaert Ad J. van Boven Ferenc Horkay Imre Ungi Samer Mansour Adrian P. Banning David P. Taggart Manel Sabaté Anthony H. Gershlick Andrzej Bochenek Jose Pomar Nicholas J. Lembo Nicolas Noiseux John D. Puskas Arie Pieter Kappetein 《Journal of the American College of Cardiology》2019,73(13):1616-1628
Background
The randomized EXCEL (Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial reported a similar rate of the 3-year composite primary endpoint of death, myocardial infarction (MI), or stroke in patients with left main coronary artery disease (LMCAD) and site-assessed low or intermediate SYNTAX scores treated with percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG). Whether these results are consistent in high-risk patients with diabetes, who have fared relatively better with CABG in most prior trials, is unknown.Objectives
In this pre-specified subgroup analysis from the EXCEL trial, the authors sought to examine the effect of diabetes in patients with LMCAD treated with PCI versus CABG.Methods
Patients (N = 1,905) with LMCAD and site-assessed low or intermediate CAD complexity (SYNTAX scores ≤32) were randomized 1:1 to PCI with everolimus-eluting stents versus CABG, stratified by the presence of diabetes. The primary endpoint was the rate of a composite of all-cause death, stroke, or MI at 3 years. Outcomes were examined in patients with (n = 554) and without (n = 1,350) diabetes.Results
The 3-year composite primary endpoint was significantly higher in diabetic compared with nondiabetic patients (20.0% vs. 12.9%; p < 0.001). The rate of the 3-year primary endpoint was similar after treatment with PCI and CABG in diabetic patients (20.7% vs. 19.3%, respectively; hazard ratio: 1.03; 95% confidence interval: 0.71 to 1.50; p = 0.87) and nondiabetic patients (12.9% vs. 12.9%, respectively; hazard ratio: 0.98; 95% confidence interval: 0.73 to 1.32; p = 0.89). All-cause death at 3 years occurred in 13.6% of PCI and 9.0% of CABG patients (p = 0.046), although no significant interaction was present between diabetes status and treatment for all-cause death (p = 0.22) or other endpoints, including the 3-year primary endpoint (p = 0.82) or the major secondary endpoints of death, MI, or stroke at 30 days (p = 0.61) or death, MI, stroke, or ischemia-driven revascularization at 3 years (p = 0.65).Conclusions
In the EXCEL trial, the relative 30-day and 3-year outcomes of PCI with everolimus-eluting stents versus CABG were consistent in diabetic and nondiabetic patients with LMCAD and site-assessed low or intermediate SYNTAX scores.(Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization [EXCEL]; NCT01205776) 相似文献9.
10.
Leopoldo Pérez de Isla Raquel Arroyo-Olivares Ovidio Muñiz-Grijalvo José Luis Diaz-Díaz Daniel Zambón Francisco Fuentes Juan F. Sánchez Muñoz-Torrero Juan Diego Mediavilla Aurora González-Estrada Jose Pablo Miramontes-González Raimundo de Andrés Marta Mauri Daniel Mosquera José M. Cepeda Lorena Suárez Miguel Ángel Barba-Romero Rosa Argüeso Pilar Álvarez-Baños Pedro Mata 《Journal of clinical lipidology》2019,13(6):989-996